ST. LOUIS, Jan. 27, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China Cardiovascular Hospital has become the first in central China to establish a robotic electrophysiology program with installation of Stereotaxis’ Robotic Magnetic Navigation technology. Chief physicians for arrhythmia treatment, Dr. Chen Ke and Dr. Song Weifeng, successfully performed their first robotic cardiac ablation procedure, treating a patient who suffered from a complex ventricular arrhythmia.
“I am very proud of our team for successfully completing our first robotic ablation procedure in under one hour, an effort that would have had added risk and taken much longer with traditional, manual methods,” said Fuwai Central China Cardiovascular Hospital Director of Arrhythmia, Professor Wang Xianqing. “Robotic Magnetic Navigation is the most advanced electrophysiology assisted catheter operating system in the world.”
Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias. Robotic cardiac ablation is performed using a soft magnetic catheter navigated inside the heart by a physician seated at a computer cockpit. The physician navigates the catheter using precise, robotically actuated magnets positioned on either side of the patient.
“Our new robotic electrophysiology program helps us achieve our mission of providing the safest and most effective treatment options for patients suffering from cardiac arrhythmias,” said Hospital President, Professor Gao Chuanyu. “We are thrilled by the initial success and see cardiac ablation as just the beginning of the potential for robotically assisted interventional procedures with Stereotaxis technology.”
“We are delighted by the success of Fuwai Central China Cardiovascular Hospital,” said David Fischel, chairman and CEO of Stereotaxis. “We applaud their leadership and look forward to supporting their continued efforts to help many more patients as they build a preeminent heart rhythm program.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
